PharmExec Blog
Follow Us
RSS
Bookstore
Tag Archives: Novartis
The Patent Black Label: Six Side-Effects of India's Novartis Glivec Ruling
Monday’s decision by India’s Supreme Court to deny a patent for the top-selling oncologic drug Glivec took nearly a decade of litigation to resolve – but the implications in and beyond India are both immediate and lasting. Here’s a list of six that Pharm Exec thinks are most important:
Posted in Emerging Markets, Global, IP, Legal, Manufacturing, Market Access, Strategy, pricing Also tagged China, Glivec, Global IP, india, oncologics, Patent, Supreme Court, TRIPs 6 Comments
European Commission Investigates J&J, Novartis
By Stephanie Sutton.
The European Commission claims that Johnson & Johnson and Novartis may have breached European antitrust rules.
Posted in Europe, Global, Guest Blog, Regulatory Also tagged antitrust, European Commission, Johnson & Johnson Leave a comment
Merck and Novartis Down in Q3 Financial Reports
By Jennifer Markarian
Pharmaceutical industry leaders Novartis and Merck—among others—released second-quarter 2012 results showing global sales down in third-quarter 2012, with growth in key pharmaceutical products helping to offset losses due to patent expirations.
Posted in Deals, Global, Guest Blog, leadership Also tagged Big Pharma, financial reports, Merck, Q3 Leave a comment
Will WHO Member States Pony Up for Neglected Diseases?
Recognizing that traditional market forces – namely incentives related to intellectual property and a steady demand for products – have failed in developing countries, the World Health Organization (WHO) asked a member state-nominated group to come up with ways to fund R&D and pay for the treatment of neglected diseases in the world’s poorest nations. [...]
Does India's Glivec Decision Make April Fools of Us All?